R&D The conflict in the Middle East is exposing dangerous prepar... If the conflict persists, the risk of widespread medicine shortages becomes increasingly real.
R&D Reshoring the UK pharmaceutical supply chain for future resi... Questions of supply chain security and resiliency have been growing in recent years.
Market Access Advancing medicine requires more secure supply chains We stand at the threshold of a new era for pharmaceutical supply chains, driven by breakthroughs in personalised medicine, the rising prevalence of biologics, and the integration of digital
R&D Threats impacting the pharmaceutical industry in 2024 As we approach 2024, what will the next 12 months have in store for pharma?
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.